Back to directory
Ambily Banerjee
CONNECT

0

Ambily Banerjee

Head of DEI, global drug development, Novartis

Ambily's professional bio / interests

Ambily started her career as a post-doctoral scientist, following a Ph.D. in Molecular Biology. After a decade as an academic scientist at Imperial College and UCL, she moved to the Pharmaceutical sector in 2007. At GSK she held increasingly senior roles in Global Regulatory Affairs, Governance, and Internal Audit. She also led a race and ethnicity Employee Resource Group at GSK, where she worked with the CEO, Chief Executive Team and Board members to highlight some of the challenges faced by ethnic minority colleagues. As a direct result of EMBRACE activities, significant actions were implemented, including aspirational targets for VP level and above and rollout of ethnic minority development programmes. She moved to Novartis 6 months ago, where her role is primarily focused on driving clinical trial diversity and also encompasses D&I for associates for Global Drug Development. Externally, Ambily is the Deputy Chair of The Network of Networks, which brings together ERG leads from 120+ organisations to share best practices. Ambily also serves on the Board of a not-for-profit ‘Micro:bit Educational Foundation’ (founded by the BBC) improving tech skills for under-represented populations. She is a Trustee for a local charity ‘Slough Council for Voluntary Services’ that has played a key role in the community response to covid-19. In 2021, Ambily received several awards in recognition of her efforts, including Investing in Ethnicity Top 10 Future Leader, No. 3 on the Empower Ethnic Minority Future Leader List, and a 2021 Healthcare Businesswomen’s Association Rising Star. She is passionate about DEI and ensuring the next generation have equal access to opportunities.

I’d like help with…

Not yet provided

An interesting, or unusual fact(s) about me…

Not yet provided

I live in

A career highlight

Not yet provided

Links

Not yet provided

Connections

0

Joined Guild

May 14, 2022